MAP2K7 and pancreatic neoplasm: Intermittent dosing may have achieved a more favourable therapeutic index, however, this theory has not borne out in similar trials testing PI3K/mTOR and MEK inhibitor combinations.17,19 The phase Ib study of buparlisib and trametinib demonstrated minimal activity in NSCLC and pancreatic cancer.